Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle.
OBJECTIVE
To investigate, in patients who previously had a suboptimal ovarian stimulation cycle, the benefit of starting ovarian stimulation before the onset of menses.


METHODS
Prospective, randomized, controlled study.


METHODS
A tertiary referral center for infertility treatment.


METHODS
Forty patients undergoing IVF or GIFT from whom only 3-6 oocytes were retrieved in their last cycle.


METHODS
Recombinant human FSH was administered before the onset of the menstrual period (experimental group) or in the early follicular phase after the onset of menses (control group).


METHODS
The number of oocytes retrieved.


RESULTS
Patients in the experimental group were ready for oocyte retrieval on menstrual cycle day 11 instead of cycle day 14. The number of oocytes retrieved was not significantly different between the two groups.


CONCLUSIONS
Poor responders do not benefit from commencing recombinant human FSH therapy in the luteal phase.
Rombauts
L
L
Monash In Vitro Fertilization, Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia.
Suikkari
A M
AM
MacLachlan
V
V
Trounson
A O
AO
Healy
D L
DL
D000328:Adult; D015331:Cohort Studies; D004958:Estradiol / Q000097:blood / Q000378:metabolism; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D007265:Inhibins / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D008183:Luteal Phase / Q000097:blood / Q000187:drug effects* / Q000502:physiology; D009865:Oocytes / Q000187:drug effects* / Q000502:physiology; D006080:Ovarian Follicle / Q000187:drug effects / Q000502:physiology; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D004958:Estradiol; D007265:Inhibins; D005640:Follicle Stimulating Hormone